OverviewSuggest Edit

Harrow Health (formerly Imprimis Pharmaceuticals) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It also owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

TypePublic
Founded2012
HQSan Diego, US
Websiteharrowinc.com

Latest Updates

Employees (est.) (Mar 2020)133
Job Openings7
Revenue (FY, 2019)$51.2 M(+24%)
Share Price (Sept 2020)$5.8 (-1%)
Cybersecurity ratingAMore

Key People/Management at Harrow Health

Mark L. Baum

Mark L. Baum

Chief Executive Officer, Member, Board of Directors
Andrew R. Boll

Andrew R. Boll

CFO
John Saharek

John Saharek

Chief Commercial Officer
Show more

Harrow Health Office Locations

Harrow Health has offices in San Diego, Irvine, Nashville and Roxbury Township
San Diego, US (HQ)
12264 El Camino Real #350
Irvine, US
9257 Research Dr
Nashville, US
102 Woodmont Blvd #610
Roxbury Township, US
1705 US-46 #6b, Ledgewood
Show all (4)

Harrow Health Financials and Metrics

Harrow Health Revenue

Harrow Health's revenue was reported to be $51.17 m in FY, 2019
USD

Revenue (Q2, 2020)

8.1m

Gross profit (Q2, 2020)

4.9m

Gross profit margin (Q2, 2020), %

60.2%

Net income (Q2, 2020)

(260.0k)

EBIT (Q2, 2020)

(3.2m)

Market capitalization (22-Sept-2020)

147.7m

Closing stock price (22-Sept-2020)

5.8

Cash (30-Jun-2020)

4.1m

EV

167.9m
Harrow Health's current market capitalization is $147.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

100.0k10.0k1.7m9.7m19.9m26.8m41.4m51.2m

Revenue growth, %

485%105%

Cost of goods sold

16.5m16.7m

Gross profit

24.9m34.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

100.0k2.5k2.5k2.5k1.4k667.7k441.0k1.6m2.0m2.7m4.4m4.9m4.9m6.1m6.9m6.5m8.9m10.4m10.7m12.3m13.5m12.8m11.8m8.1m

Cost of goods sold

4.2m4.2m3.9m5.2m4.1m3.6m3.2m

Gross profit

6.2m6.5m8.4m8.3m8.7m8.2m4.9m

Gross profit Margin, %

60%61%68%61%68%69%60%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

146.2k10.0m15.6m8.2m2.7m8.9m4.0m6.8m4.9m

Accounts Receivable

81.3k840.0k2.9m1.5m1.9m2.0m

Prepaid Expenses

14.8k61.6k105.1k240.4k786.0k714.0k837.0k1.3m

Inventories

372.7k1.4m1.8m2.2m1.8m3.3m
USDQ2, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Harrow Health Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Harrow Health Online and Social Media Presence

Embed Graph

Harrow Health News and Updates

Harrow Health to Announce Second Quarter 2020 Financial Results on August 10, 2020

NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific…

Harrow Health Set to Join Russell 2000® Index and Russell 3000® Index

NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US marke…

Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders

NASHVILLE, Tenn., March 13, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2019.  Please click here to review Harrow Health’s Letter to Stockholders for the fourth quarter 2019.

Harrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020

NASHVILLE, Tenn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific …

Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health

ROSELAND, N.J., Dec. 10, 2019 /PRNewswire/ -- Novel Drug Solutions, LLC and Eye Care Northwest, PA, announce the return of their unrestricted patent rights to several awarded and pending USA and international patents previously controlled by Harrow Health, Inc. (NASDAQ: HROW formerly...

Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019

NASHVILLE, Tenn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pac…
Show more

Harrow Health Blogs

Harrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020

Harrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020

Harrow Health Appoints Teresa Sparks to its Board of Directors

Harrow Health Appoints Teresa Sparks to its Board of Directors

ImprimisRx® Announces Supply Agreement with iOR Partners

ImprimisRx® Announces Supply Agreement with iOR Partners

Harrow Health Publishes Third Quarter Letter to Stockholders

Harrow Health Publishes Third Quarter Letter to Stockholders

Harrow Health Announces Second Quarter 2019 Results

Harrow Health Announces Second Quarter 2019 Results

Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics

Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
Show more

Harrow Health Frequently Asked Questions

  • When was Harrow Health founded?

    Harrow Health was founded in 2012.

  • Who are Harrow Health key executives?

    Harrow Health's key executives are Mark L. Baum, Andrew R. Boll and John Saharek.

  • How many employees does Harrow Health have?

    Harrow Health has 133 employees.

  • What is Harrow Health revenue?

    Latest Harrow Health annual revenue is $51.2 m.

  • What is Harrow Health revenue per employee?

    Latest Harrow Health revenue per employee is $384.7 k.

  • Who are Harrow Health competitors?

    Competitors of Harrow Health include Antidote Therapeutics, Sollis Therapeutics and Zhimeng Biopharma.

  • Where is Harrow Health headquarters?

    Harrow Health headquarters is located at 12264 El Camino Real #350, San Diego.

  • Where are Harrow Health offices?

    Harrow Health has offices in San Diego, Irvine, Nashville and Roxbury Township.

  • How many offices does Harrow Health have?

    Harrow Health has 4 offices.